secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001737287-23-000089
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track
------------------------------------------------------------------

- Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.
- Cash, equivalents and investments $497.7M as of Sept 30, 2023; runway into 2H 2025.
- 2023 guidance: cash use ~$230M; GAAP op. expense ~$340M incl. ~$80M stock comp.
- ALPHA2 Phase 2 trial for ALLO-501A in LBCL enrolling; completion expected 1H 2024, data by end 2024.
- New CFO Geoffrey Parker and General Counsel Earl Douglas appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/0001737287-23-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/allo-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer